KR100269879B1 - 항-이알비비-2모노클로날항체의 조합물 및 그 사용방법 - Google Patents

항-이알비비-2모노클로날항체의 조합물 및 그 사용방법 Download PDF

Info

Publication number
KR100269879B1
KR100269879B1 KR1019940701148A KR19940701148A KR100269879B1 KR 100269879 B1 KR100269879 B1 KR 100269879B1 KR 1019940701148 A KR1019940701148 A KR 1019940701148A KR 19940701148 A KR19940701148 A KR 19940701148A KR 100269879 B1 KR100269879 B1 KR 100269879B1
Authority
KR
South Korea
Prior art keywords
antibody
combination
erbb
antibodies
amino acid
Prior art date
Application number
KR1019940701148A
Other languages
English (en)
Korean (ko)
Other versions
KR950700075A (ko
Inventor
필립지.카스프르직
찰스알.킹
Original Assignee
폴 에이치. 피셔
온콜로직스,인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 폴 에이치. 피셔, 온콜로직스,인코포레이티드 filed Critical 폴 에이치. 피셔
Publication of KR950700075A publication Critical patent/KR950700075A/ko
Application granted granted Critical
Publication of KR100269879B1 publication Critical patent/KR100269879B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1019940701148A 1992-06-30 1992-10-21 항-이알비비-2모노클로날항체의 조합물 및 그 사용방법 KR100269879B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90655592A 1992-06-30 1992-06-30
US07/906,555 1992-06-30
PCT/US1992/008545 WO1994000136A1 (en) 1992-06-30 1992-10-21 A COMBINATION OF ANTI-erbB-2 MONOCLONAL ANTIBODIES AND METHOD OF USING

Publications (2)

Publication Number Publication Date
KR950700075A KR950700075A (ko) 1995-01-16
KR100269879B1 true KR100269879B1 (ko) 2000-10-16

Family

ID=25422648

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940701148A KR100269879B1 (ko) 1992-06-30 1992-10-21 항-이알비비-2모노클로날항체의 조합물 및 그 사용방법

Country Status (6)

Country Link
EP (1) EP0655924A4 (ja)
JP (1) JPH08504172A (ja)
KR (1) KR100269879B1 (ja)
AU (1) AU687346B2 (ja)
CA (1) CA2120745A1 (ja)
WO (1) WO1994000136A1 (ja)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733752B1 (en) 1994-03-30 2004-05-11 The Trustees Of The University Of Pennsylvania Prevention of tumors with monoclonal antibodies against neu
US5759776A (en) * 1995-06-05 1998-06-02 California Pacific Medical Center Targets for breast cancer diagnosis and treatment
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP1947119A3 (en) 1997-12-12 2012-12-19 Genentech, Inc. Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
EP1941905A1 (en) 1998-03-27 2008-07-09 Genentech, Inc. APO-2 Ligand-anti-her-2 antibody synergism
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP2283867B1 (en) 1999-06-25 2014-05-21 ImmunoGen, Inc. Methods of treatment using anti-ERBB antibody-maytansinoid conjugates
CN100340575C (zh) 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
TR200200472T2 (tr) 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US20030152572A1 (en) * 2000-04-06 2003-08-14 Yoshimi Homma Diagnostic and therapeutic agents for rheumatoid arthritis
SI2857516T1 (sl) 2000-04-11 2017-09-29 Genentech, Inc. Multivalentna protitelesa in njihove uporabe
CN102698265A (zh) 2000-05-19 2012-10-03 杰南技术公司 用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
SI1501856T1 (sl) 2002-04-10 2013-04-30 Genentech, Inc. Variante protitelesa proti HER2
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
PT2263691E (pt) 2002-07-15 2012-11-12 Hoffmann La Roche Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4)
CN100408097C (zh) * 2002-10-10 2008-08-06 默克专利有限公司 双特异性抗erb-b抗体及其在肿瘤治疗中的用途
SI1549344T1 (sl) * 2002-10-10 2015-05-29 Merck Patent Gmbh FARMACEVTSKI SESTAVKI PROTI RECEPTORJEM ErbB1
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
EP1737489B1 (en) 2004-04-08 2012-01-11 David B Agus ErbB2 antagonists for tumor pain therapy
KR20180091967A (ko) 2004-07-22 2018-08-16 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR20170134771A (ko) 2005-01-21 2017-12-06 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
KR101253576B1 (ko) 2005-02-23 2013-04-11 제넨테크, 인크. Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
SI2511301T1 (en) 2006-08-04 2018-05-31 MedImmune Limited, Human antibodies to ERBB 2
JP5726417B2 (ja) 2007-03-01 2015-06-03 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ 組み換え抗上皮成長因子受容体抗体組成物
EP2899541A1 (en) 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
PL3327026T3 (pl) 2007-07-09 2020-02-28 Genentech, Inc. Zapobieganie redukcji wiązań disiarczkowych podczas rekombinacyjnego wytwarzania polipeptydów
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CA2732856C (en) 2008-08-29 2018-08-28 Symphogen A/S Cancer treatment with a combination of two different anti-epidermal growth factor receptor antibodies
AR075896A1 (es) 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
SG10201507044PA (en) 2009-05-29 2015-10-29 Hoffmann La Roche Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
KR101822205B1 (ko) 2009-08-11 2018-01-25 제넨테크, 인크. 글루타민-비함유 세포 배양 배지에서의 단백질의 생성
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
AU2011239583A1 (en) 2010-04-15 2012-11-29 Alper Biotech, Llc Monoclonal antibodies against HER2 antigens, and uses therefor
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
RU2586515C2 (ru) 2010-12-21 2016-06-10 Ф.Хоффманн-Ля Рош Аг Препарат антитела, обогащенного изоформами и способ его получения
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
JP6297490B2 (ja) 2011-08-31 2018-03-20 ジェネンテック， インコーポレイテッド 診断マーカー
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
KR20210090298A (ko) 2012-10-30 2021-07-19 에스퍼란스 파마슈티컬스, 인코포레이티드 항체/약물 컨쥬게이트 및 이의 사용 방법
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
KR101453462B1 (ko) 2013-05-16 2014-10-23 앱클론(주) Her2에 특이적으로 결합하는 항체
CA2943299A1 (en) 2014-04-11 2015-10-15 Medimmune, Llc Bispecific her2 antibodies
EP3131584B1 (en) 2014-04-16 2022-01-12 Biocon Limited Stable protein formulations comprising a molar excess of sorbitol
IL292708B1 (en) 2015-05-30 2024-04-01 Molecular Templates Inc Vaccine-free Shiga toxin A subunit scaffolds and cell-targeting molecules containing them
AU2016280159A1 (en) 2015-06-17 2017-12-07 Genentech, Inc. Anti-HER2 antibodies and methods of use
JP7386796B2 (ja) 2017-11-14 2023-11-27 グリーン クロス ラボ セル コーポレーション 抗－ｈｅｒ２抗体又はその抗原結合フラグメント、及びこれを含むキメラ抗原受容体
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CA3097178A1 (en) 2018-04-17 2019-10-24 Molecular Templates, Inc. Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds
EP3560945A1 (en) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Methods for purification of polypeptides using polysorbates
JP2022532812A (ja) * 2018-08-16 2022-07-20 カンタージア アクチエボラーグ 抗ｉｌ１ｒａｐ抗体組成物
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867962A (en) * 1988-02-26 1989-09-19 Neorx Corporation Functionally specific antibodies
EP0494135B1 (en) * 1989-09-29 1996-04-10 Oncogene Science, Inc. Human "neu" related protein p100 and use of the same for detecting preneoplastic or neoplastic cells in a human

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Research Vol. 50:1550-1558(1990. 3.) *

Also Published As

Publication number Publication date
CA2120745A1 (en) 1994-01-06
KR950700075A (ko) 1995-01-16
AU687346B2 (en) 1998-02-26
WO1994000136A1 (en) 1994-01-06
EP0655924A4 (en) 1996-09-11
EP0655924A1 (en) 1995-06-07
AU3773393A (en) 1994-01-24
JPH08504172A (ja) 1996-05-07

Similar Documents

Publication Publication Date Title
KR100269879B1 (ko) 항-이알비비-2모노클로날항체의 조합물 및 그 사용방법
DE69630313T3 (de) Mit monoklonalem antikörper anti-her2 induzierte apoptosis
JP4318752B2 (ja) 抗エンドグリンモノクローナル抗体および抗血管新生治療におけるその使用
JP3213314B2 (ja) 幹細胞因子レセプターに対するモノクローナル抗体
EP2635605B1 (en) Anti-her3 antibodies and compositions
AU2006332212B8 (en) Combination therapy using anti-EGFR and anti-HER2 antibodies
JP6326137B2 (ja) 抗ｈｅｒ２抗体及びその結合体
CA2682296C (en) Anti-epcam antibody and uses thereof
US8734799B2 (en) Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer
US20030165502A1 (en) Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US20080177047A1 (en) Single-chain Antibodies Against Human Insulin-Like Growth Factor I Receptor: Expression, Purification, and Effect on Tumor Growth
TWI478939B (zh) 使用特定抗－ｌ１抗體治療腫瘤
KR20120060235A (ko) 특이성 결합 단백질 및 용도
CN116096897A (zh) 抗4-1bb-抗pd-l1双特异性抗体、其药物组合物及用途
TWI817190B (zh) 抗ｃ-Ｍｅｔ抗體藥物偶聯物及其應用
EP3082858B1 (en) Adrenomedullin binder for use in therapy of cancer
TW202207993A (zh) 位點特異性her2抗體-藥物共軛物之治療
WO2015138411A1 (en) Anti-fibulin-3 antibodies and uses thereof
JPH115749A (ja) 癌治療医薬品組成物
KR20190023084A (ko) 이중 특이성 항체를 이용한 항체 약물 복합체 플랫폼
TW202305008A (zh) 三特異性抗體、其製備方法和用途
CN117430711A (zh) 用于治疗肝细胞性肝癌的双特异性融合蛋白及其应用
CN116333143A (zh) Scube2中和抗体及其医药用途
US20100119514A1 (en) Antibodies Against Cancer
BR112013010764A2 (pt) composição de anticorpos anti-her3, molécula de ligação biespecífica, molécula de ácido nucleico, vetor de expressão, linhagem celular policlonal, método para produção da referida composição, composição farmacêutica e uso da referida composição

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030714

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee